MS treatments include immunosuppressants (i.e., fingolimod), immunomodulatory therapies (i.e., IFN-β and DMF), and immune reconstitution therapies (i.e., alemtuzumab and cladribine) (Dobson and Giovannoni, 2019). The gene discussed is IFNB1; the disease is myeloid sarcoma.